Myriad facing competition post-SCOTUS, as myRisk doubts raised
This article was originally published in Clinica
Executive Summary
Myriad Genetics is already facing competition from rivals keen to cash in on the recent US Supreme Court decision that DNA is not patentable, but complementary DNA (cDNA) is. The company was defending its patents on the BRCA1 and BRCA2 genes, which are used in its flagship BRACAnalysis test to evaluate the risk of a woman developing hereditary breast or ovarian cancer.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.